1. LEADER One Year On

3. Topics for Discussion

4. LEADER: Study Design

5. LEADER: Primary Outcome Measure*

6. LEADER: Death From CV Causes

7. LEADER: HHF

8. LEADER: Time to First Renal Event*

9. LEADER: Primary Outcome Subgroup Analyses

10. LEADER: Study Population Baseline CV Risk Profile

11. LEADER: Overall Summary of AEs

12. LEADER: Selected AEs of Special Interest

13. Completed CVOTs in T2DM

14. SUSTAIN 6: Study Design

15. SUSTAIN-6: Primary Outcome Measure*

16. SUSTAIN-6: CV Endpoints

17. ELIXA: Primary Outcome Measure*

18. GLP-1 RAs: Overview of Clinical Characteristics and Pharmacokinetics

19. ELIXA, LEADER, and SUSTAIN-6: Similarities and Differences

20. CV Outcomes for DPP-4 Inhibitors

21. SAVOR-TIMI 53, EXAMINE, and TECOS: HHF

22. DPP-4 Inhibitors and HF Risk

23. EMPA-REG OUTCOME: Trial Design

24. EMPA-REG OUTCOME: Primary Outcome Measure*

25. EMPA-REG OUTCOME: HHF

26. Similarities and Differences of Patient Characteristics in EMPA-REG OUTCOME and LEADER

27. EMPA-REG OUTCOME: CV Death, MI, and Stroke

28. Cross-Trial Comparisons

29. EMPA-REG OUTCOME Microvascular Outcomes: Renal Protection

30. GLP-1 RAs: Is There a Relationship Between Half-Life and Clinical Outcomes?

31. Potential Mechanisms of SGLT2 Inhibitors Resulting in CV Outcomes

32. EXSCEL: Top-Line Results

33. Available Evidence From CVOTs and Patients With T2DM

34. SGLT2 Inhibitors and Lower-Limb Amputations

35. Candidates for Antihyperglycemic Therapy With Effects on CV Outcomes: Empagliflozin, Liraglutide, Semaglutide

36. 2017 ADA Standards of Medical Care in Diabetes

37. Should SGLT2 Inhibitors and GLP-1 RAs Be Combined to Provide Extreme CV Benefits?

38. Summary and Conclusions

39. Summary and Conclusions (cont)

40. Abbreviations

41. Abbreviations (cont)

42. Abbreviations (cont)